E. Ohman J or Asset Management AB Has $37.50 Million Stake in Boston Scientific Co. (NYSE:BSX)

E. Ohman J or Asset Management AB trimmed its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 36.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 371,700 shares of the medical equipment provider's stock after selling 210,245 shares during the period. Boston Scientific makes up approximately 1.0% of E. Ohman J or Asset Management AB's holdings, making the stock its 26th biggest holding. E. Ohman J or Asset Management AB's holdings in Boston Scientific were worth $37,497,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Investment Management Corp VA ADV acquired a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $25,000. Colonial Trust Co SC increased its stake in Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 260 shares in the last quarter. TFC Financial Management Inc. increased its stake in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 210 shares in the last quarter. Sunbeam Capital Management LLC bought a new stake in Boston Scientific during the 4th quarter worth approximately $26,000. Finally, Ameriflex Group Inc. bought a new stake in Boston Scientific during the 4th quarter worth approximately $31,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research reports. Evercore ISI increased their target price on Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. BTIG Research reaffirmed a "buy" rating and set a $124.00 price target on shares of Boston Scientific in a research note on Wednesday, April 23rd. Truist Financial raised their price target on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Barclays raised their price target on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Finally, Argus set a $130.00 price target on shares of Boston Scientific in a research note on Tuesday, February 18th. Twenty-one analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Boston Scientific has a consensus rating of "Buy" and an average target price of $116.00.

Insider Activity

In related news, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the transaction, the senior vice president now owns 36,193 shares of the company's stock, valued at $3,441,592.37. The trade was a 11.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.48, for a total value of $16,852,118.64. Following the completion of the transaction, the chief executive officer now directly owns 1,535,706 shares of the company's stock, valued at approximately $157,379,150.88. This trade represents a 9.67% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 411,970 shares of company stock valued at $42,406,693. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Performance

Boston Scientific stock traded down $0.79 during trading hours on Friday, hitting $102.04. The company had a trading volume of 9,114,389 shares, compared to its average volume of 6,467,344. The firm has a market cap of $150.96 billion, a PE ratio of 81.63, a PEG ratio of 2.79 and a beta of 0.68. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a one year low of $71.88 and a one year high of $107.17. The firm has a 50-day moving average of $100.49 and a 200 day moving average of $98.37.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The company had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Boston Scientific's quarterly revenue was up 20.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.56 earnings per share. On average, sell-side analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.